JP2023503283A - 放射線治療の為の予防的な皮膚処置 - Google Patents

放射線治療の為の予防的な皮膚処置 Download PDF

Info

Publication number
JP2023503283A
JP2023503283A JP2022529271A JP2022529271A JP2023503283A JP 2023503283 A JP2023503283 A JP 2023503283A JP 2022529271 A JP2022529271 A JP 2022529271A JP 2022529271 A JP2022529271 A JP 2022529271A JP 2023503283 A JP2023503283 A JP 2023503283A
Authority
JP
Japan
Prior art keywords
dfo
skin
radiation
treatment
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503283A5 (enExample
Inventor
ワン，デリック，シー．
ロンゲーカー，マイケル，ティー．
シー． ガートナー，ジェフリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2023503283A publication Critical patent/JP2023503283A/ja
Publication of JP2023503283A5 publication Critical patent/JP2023503283A5/ja
Priority to JP2025033377A priority Critical patent/JP2025084944A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022529271A 2019-11-20 2020-10-20 放射線治療の為の予防的な皮膚処置 Pending JP2023503283A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025033377A JP2025084944A (ja) 2019-11-20 2025-03-04 放射線治療の為の予防的な皮膚処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962938209P 2019-11-20 2019-11-20
US62/938,209 2019-11-20
PCT/US2020/056421 WO2021101646A1 (en) 2019-11-20 2020-10-20 Prophylactic skin treatment for radiation therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025033377A Division JP2025084944A (ja) 2019-11-20 2025-03-04 放射線治療の為の予防的な皮膚処置

Publications (2)

Publication Number Publication Date
JP2023503283A true JP2023503283A (ja) 2023-01-27
JP2023503283A5 JP2023503283A5 (enExample) 2023-06-22

Family

ID=75980773

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022529271A Pending JP2023503283A (ja) 2019-11-20 2020-10-20 放射線治療の為の予防的な皮膚処置
JP2025033377A Pending JP2025084944A (ja) 2019-11-20 2025-03-04 放射線治療の為の予防的な皮膚処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025033377A Pending JP2025084944A (ja) 2019-11-20 2025-03-04 放射線治療の為の予防的な皮膚処置

Country Status (6)

Country Link
US (2) US12403106B2 (enExample)
EP (1) EP4061402A4 (enExample)
JP (2) JP2023503283A (enExample)
CN (1) CN115279394A (enExample)
BR (1) BR112022009804A2 (enExample)
WO (1) WO2021101646A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025111378A1 (en) * 2023-11-20 2025-05-30 Tautona Group Ip Holding Company, L.L.C. Semi-solid formulations of deferoxamine for the treatment of radiation therapy burns

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069623A1 (en) * 2007-08-21 2009-03-12 Virginia Commonwealth University Intellectual Property Foundation Methods and compositions for treatment or prevention of radiation-induced fibrosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE26914C (de) 1883-06-19 1884-05-08 CH E. SACKETT in Wayne-Township, Pennsylvanien, V. St. A Ackergeräth zum Pflügen und Zerkleinern der Erde
EP1585548B1 (en) * 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US8303973B2 (en) 2004-09-17 2012-11-06 Angiotech Pharmaceuticals (Us), Inc. Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
WO2006078717A2 (en) 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
CA2947330C (en) 2005-09-16 2018-06-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20100068279A1 (en) 2006-11-28 2010-03-18 Ats Biotech Inc. Burn bandage
US20090198332A1 (en) 2008-02-05 2009-08-06 Hilton Becker Method for texturing the surface of a synthetic implant
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
AU2010286054B2 (en) 2009-08-19 2016-10-27 Mordechai Chevion Desferrioxamine-metal complexes for the treatment of immune-related disorders
US8377062B2 (en) 2009-12-17 2013-02-19 Stryker Trauma Gmbh Therapeutic agent capsule for implants
US20140377320A1 (en) 2011-12-22 2014-12-25 Chuv, Centre Hospitalier Universitaire Vaudois Selective Plasma Activation for Medical Implants and Wound Healing Devices
US9737395B2 (en) 2015-06-26 2017-08-22 Phi Nguyen Systems and methods for reducing scarring
US10933174B2 (en) 2016-05-03 2021-03-02 Medtronic, Inc. Hemostatic devices and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069623A1 (en) * 2007-08-21 2009-03-12 Virginia Commonwealth University Intellectual Property Foundation Methods and compositions for treatment or prevention of radiation-induced fibrosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANN PLAST SURG, vol. 81(5), JPN6024020315, 2018, pages 604 - 608, ISSN: 0005333660 *
PNAS, vol. 112, no. 1, JPN6024044310, 2015, pages 94 - 99, ISSN: 0005452643 *

Also Published As

Publication number Publication date
US20220409559A1 (en) 2022-12-29
JP2025084944A (ja) 2025-06-03
BR112022009804A2 (pt) 2022-08-16
US12403106B2 (en) 2025-09-02
EP4061402A4 (en) 2023-12-06
US20250375400A1 (en) 2025-12-11
WO2021101646A1 (en) 2021-05-27
EP4061402A1 (en) 2022-09-28
CN115279394A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
Borrelli et al. Radiation-induced skin fibrosis: pathogenesis, current treatment options, and emerging therapeutics
Chen et al. Layered GelMA/PEGDA hydrogel microneedle patch as an intradermal delivery system for hypertrophic scar treatment
Zeng et al. Neddylation suppression by a macrophage membrane-coated nanoparticle promotes dual immunomodulatory repair of diabetic wounds
US20250262176A1 (en) Conditioning Irradiated Tissue for Increasing Vascularity
US20250375400A1 (en) Prophylactic skin treatment for radiation therapy
Fang et al. Improvement of skin wound healing for diabetic mice with thermosensitive hydrogel combined with insulin injection
Qu et al. ALA-PDT promotes the death and contractile capacity of hypertrophic scar fibroblasts through inhibiting the TGF-β1/Smad2/3/4 signaling pathway
Mericli et al. Deferoxamine mitigates radiation-induced tissue injury in a rat irradiated TRAM flap model
Yu et al. Exendin-4 promotes ischemia-reperfusion flap survival by upregulating Gpx4 to inhibit ferroptosis
JP7001736B2 (ja) 血管破壊剤を含む肝臓癌治療用の組成物
Priya et al. Concurrent occurrence of lobular capillary haemangioma and port-wine stain: a case report and literature review
Georgoulis et al. Pyogenic Granuloma: A Literature Review and a Case Report
US20220409688A1 (en) Pharmaceutical composition for use in increasing hair, modifying scalp or skin, healing a wound, promoting osteogenesis, or modifying hair
Isomura et al. Inferior alveolar nerve regeneration after bifocal distraction osteogenesis in dogs
US20210093662A1 (en) Gold Particle for Use in Therapy to Prevent Scar Formation
Surowiak et al. Platelet-rich plasma stimulates collagen type I synthesis in the human skin: a placebo-controlled in vivo study
Al-Ankily et al. Epidermal growth factor and diabetes mellitus; friends or faux?
Yamazaki et al. Radiation induces pericyte-myofibroblast transition
Elkhodary et al. Effect of Low-Level Laser Therapy Versus Shock Wave on Diabetic Foot.
Kim et al. Intralesional platelet-rich plasma injection promotes tongue regeneration following partial glossectomy in a murine model
Brewer et al. Multiphoton imaging of excised normal skin and keloid scar: preliminary investigations
Frontczak-Baniewicz et al. The immature endothelial cell in human glioma. Ultrastructural features of blood capillary vessels
Siegel et al. Topical delivery of a PPARγ agonist enables adipogenic repair of irradiated skin
Morgun et al. The Model of an Ischemic Non-Healing Wound: Regeneration after Transplantation of a Living Skin Equivalent
Campiglio et al. Post-burn and Keloid Scar Treatment with Adipose-Derived Stem Cells (ADSC)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250304